TriSalus Life Sciences, Inc. (TLSI)
5.07
-0.07
(-1.36%)
USD |
NASDAQ |
Sep 03, 10:01
TriSalus Life Sciences Debt to Equity Ratio : 5.256 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 5.256 |
| March 31, 2026 | 2.693 |
| December 31, 2025 | -1.017 |
| September 30, 2025 | -1.277 |
| June 30, 2025 | -1.733 |
| March 31, 2025 | -0.9635 |
| December 31, 2024 | -0.9125 |
| September 30, 2024 | -1.148 |
| June 30, 2024 | -0.9426 |
| March 31, 2024 | -0.0453 |
| December 31, 2023 | -0.0589 |
| September 30, 2023 | 0.20 |
| Date | Value |
|---|---|
| June 30, 2023 | -1.083 |
| March 31, 2023 | 0.4779 |
| December 31, 2022 | -0.1593 |
| September 30, 2022 | 0.0069 |
| June 30, 2022 | 0.0061 |
| March 31, 2022 | 0.0034 |
| December 31, 2021 | 0.0023 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| September 30, 2020 | 1.771 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
| Vericel Corp. | 0.2556 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 62.45M |
| Total Liabilities (Quarterly) | 55.90M |
| Shareholders Equity (Quarterly) | 6.55M |
| Current Ratio | 5.348 |
| Net Debt Paydown Yield | -0.09% |